Question explored with the scientific record
Felodopine
Felodipine lowers blood pressure, but the evidence for it is old, thin, and funded by the manufacturer.
The evidence you have is a stack of small, short-term studies from the 1990s and early 2000s. One trial compared felodipine to another calcium channel blocker and found it worked better but caused more side effects like swelling, flushing, and headache [1]. Another year-long trial in 171 people with mild hypertension showed it lowered systolic pressure by about 12 mmHg more than placebo and improved some quality-of-life scores [6]. That trial was funded by the drug's maker, AstraZeneca [6]. A third study combined felodipine with ramipril and found it reduced carotid artery wall thickness, but that was a small, uncontrolled observation [7].
None of these studies tracked hard outcomes like heart attacks, strokes, or death. They measured surrogate endpoints: blood pressure numbers and artery thickness. A 1993 study also noted a small but statistically significant rise in total cholesterol with felodipine, about 0.3 mmol/L [1]. That is a signal worth watching, but it was never followed up in a long-term trial.
The most recent study here is from 2017, and it is about making the drug dissolve better, not about whether it helps you live longer [3]. The safety data on drug interactions is also thin. One 2013 analysis of spontaneous reports flagged a signal for heart failure when felodipine was taken with the antifungal itraconazole, but that is a correlation, not proof [8].
| Outcome | Felodipine | Comparator | Source |
|---|---|---|---|
| SBP reduction (52 weeks) | -11.7 mmHg | -2.0 mmHg (placebo) | [6] |
| DBP reduction (52 weeks) | -3.0 mmHg | -0.1 mmHg (placebo) | [6] |
| Response rate (6 weeks) | 90% | 71% (nitrendipine) | [1] |
| Total cholesterol change | +0.30 mmol/L | Unchanged | [1] |
| Peripheral edema | More common | Less common | [1] |
My call: felodipine lowers blood pressure in the short term, but the evidence base is decades old, funded by the manufacturer, and never tested against real clinical outcomes. The long-term safety data does not exist. Confidence: low.
Sources used 8
-
Antihypertensive efficacy and safety of felodipine compared with nitrendipine in mild to moderate hypertension
This study compares the antihypertensive efficacy and safety of felodipine and nitrendipine in patients with mild to moderate hypertension, finding that felodipine is more effective in reducing blood pressure but associated with more adverse effects.
DOI: 10.1016/s0011-393x(05)80737-4 -
Efficacy and Safety of Felodipine, A New Dihydropyridine Calcium Channel Blocker, in Elderly Hypertensive Patients
This study evaluates the efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in treating elderly hypertensive patients, highlighting its favorable pharmacokinetic profile and minimal adverse effects compared to traditional antihypertensive therapies.
DOI: 10.3109/10641969209038187 -
Multicomponent solid forms of felodipine: preparation, characterisation, physicochemical and in-vivo studies
This study successfully demonstrates the mechanochemical synthesis of multicomponent solid forms of the poorly soluble antihypertensive drug felodipine, leading to significant improvements in solubility and bioavailability compared to the pure drug.
DOI: 10.1111/jphp.12685 -
Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine
This study compares the blood pressure-lowering effects of felodipine administered as extended release tablets once or twice daily versus plain tablets twice daily in hypertensive patients, finding no significant differences in blood pressure control among the regimens.
DOI: 10.1007/BF00314915 -
Does QTc Interval Predict the Response to β-Blockers and Calcium Channel Blockers in Hypertensives?
This historical reanalysis of five antihypertensive trials assessed whether QTc interval, pretreatment heart rate, or heart rate change predict blood pressure response to β1-selective blockers (nebivolol) or dihydropyridine calcium channel blockers (amlodipine, felodipine, nifed…
DOI: 10.1097/01.hdx.0000080716.21869.a1 -
One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension
A randomized, double-blind trial in older adults with stage 1 isolated systolic hypertension showed that felodipine extended-release significantly lowered trough systolic blood pressure and improved left ventricular hypertrophy prevalence and quality of life over 52 weeks compar…
DOI: 10.1161/hy1101.095000 -
The effects of antihypertensive therapy on carotid vascular structure in man
This study investigates the impact of antihypertensive therapy with ramipril and felodipine on carotid intima-media thickness (IMT) in hypertensive patients, finding significant regression of IMT associated with blood pressure reduction.
DOI: 10.1016/s0008-6363(95)00026-7 -
A Quantitative Analysis of the Spontaneous Reporting of Congestive Heart Failure‐Related Adverse Events With Systemic Anti‐Fungal Drugs
Itraconazole shows a persistent, drug-specific signal for congestive heart failure-related adverse events in spontaneous reporting, especially with polypharmacy, while other antifungals show no consistent SDRs, arguing against a pharmacological or therapeutic class effect.
DOI: 10.1002/jcph.84